Requirement of ADP for arachidonic acid-induced platelet aggregation: studies with selective thromboxane-synthase inhibitors.

[1]  W. Buczko,et al.  High Pressure Liquid Chromatography Microassay for Platelet Serotonin , 1984, Thrombosis and Haemostasis.

[2]  J. Burch,et al.  Sodium arachidonate induced platelet aggregation is independent of secreted adenosine diphosphate. , 1983, Thrombosis research.

[3]  E. Dejana,et al.  Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma". , 1983, Science.

[4]  W. Surewicz,et al.  The effect of local anaesthetics on the osmotic fragility of liposomes. , 1982, Biochemical pharmacology.

[5]  G. L. Le Breton,et al.  Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. , 1982, The Journal of pharmacology and experimental therapeutics.

[6]  H. Deckmyn,et al.  A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. , 1982, Thrombosis research.

[7]  E. Macarak,et al.  Bovine endothelial cells in culture produce thromboxane as well as prostacyclin. , 1981, The Journal of clinical investigation.

[8]  E. Dejana,et al.  Effects of an Epoxymethano Stable Analogue of Prostaglandin Endoperoxides (U-46619) on Human Platelets , 1981, Thrombosis and Haemostasis.

[9]  Huang Em,et al.  Reassessment of the evidence for the role of secreted ADP in biphasic platelet aggregation. Mechanism of inhibition by creatine phosphate plus creatine phosphokinase. , 1980 .

[10]  G. Minno,et al.  Prostaglandins as Inhibitors of Human Platelet Aggregation , 1979, British journal of haematology.

[11]  T. Martin,et al.  Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets. , 1979, Biochimica et biophysica acta.

[12]  P. Needleman,et al.  Arachidonic acid-induced platelet aggregation independent of ADP-release in a patient with a bleeding disorder due to platelet storage pool disease. , 1979, Thrombosis research.

[13]  R. Feinman,et al.  Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion , 1977, Nature.

[14]  E. Salzman.  Interralation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3′,5′-adenosine monophosphate in human blood platelets , 1977 .

[15]  J. Mustard,et al.  Sodium arachidonate can induce platelet shape change and aggregation which are independent of the release reaction. , 1976, Science.

[16]  H. Weiss,et al.  Prostaglandin E2 Potentiation of Platelet Aggregation Induced by LASS Endoperoxide: Absent in Storage Pool Disease, Normal after Aspirin Ingestion , 1976, British journal of haematology.

[17]  M. Hamberg,et al.  The role of prostaglandin endoperoxides and thromboxanes in platelet aggregation. , 1976, Advances in prostaglandin and thromboxane research.

[18]  J. Smith,et al.  Arachidonic acid-induced human platelet aggregation and prostaglandin formation. , 1973, Prostaglandins.

[19]  A. Hellem,et al.  Adenosine Diphosphate in Red Cells as a Factor in the Adhesiveness of Human Blood Platelets , 1961, Nature.

[20]  L. Lorand,et al.  Studies on apyrases. , 1961, Archives of biochemistry and biophysics.